USFDA completes audit of Louisiana-based facility with no observations: Dr Reddys

Published On 2019-08-11 04:18 GMT   |   Update On 2019-08-11 04:18 GMT

As per the USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts.


New Delhi: Dr Reddy's Laboratories on August 9 said the US health regulator has completed an audit of its Louisiana-based formulations manufacturing facility, following which no form 483 was issued.


The audit of our formulations manufacturing facility at Shreveport, Louisiana, USA by the US Food and Drug Administration (USFDA), has been completed on August 8, 2019. No Form 483 was issued at the end of the inspection, the company said in a regulatory filing.


Also Read: Dr Reddys unveils a generic version of Vitamin K1 injection in the US


As per the USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts.


It notifies the company's management of objectionable conditions.



Based in Hyderabad, Dr Reddys was founded by Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited, of Hyderabad, India.

Also Read: Dr Reddys gets 5 USFDA observations for Bollaram plant

Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News